Drug
RP L102
RP L102: highest development phase Phase 2, developed by Rocket Pharmaceuticals. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Rocket Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| RP-L102 NCT04069533 | Phase 2 | Fanconi Anemia Complementation Group A |
| RP-L102 NCT04248439 | Phase 2 | Fanconi Anemia Complementation Group A |
| RP-L102 NCT03814408 | Phase 1 | Fanconi Anemia Complementation Group A |
Latest
No recent events.
Follow RP L102 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.